Vactosertib, a Novel Transforming Growth Factor Beta (TGFβ) Type I Receptor Kinase Inhibitor, Improves T-Cell Fitness: A Single-Arm, Phase Ib Trial in Relapsed or Refractory Multiple Myeloma (RRMM)

被引：0
|
作者：
Malek, Ehsan [1 ,2 ]
Rana, Priyanka [1 ,2 ]
Daunov, Michael [1 ,2 ]
Miyagi, Masaru [1 ,2 ]
Ignatz-Hoover, James [1 ,2 ]
Metheny, Leland [1 ,2 ]
Driscoll, James [1 ,2 ]
机构：
[1] Univ Hosp Cleveland, Div Hematol Oncol, Cleveland, OH 44106 USA
[2] Case Comprehens Canc Ctr, Cleveland, OH USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷
关键词：
multiple myeloma (MM); transforming growth factor beta (TGFb) receptor kinase inhibitor; cytotoxic T lymphocyte; immunosuppression; T-cell fitness;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MM-514
引用
收藏
页码：S505 / S506
页数：2
相关论文
共 23 条
  • [11] A phase 2 study of a novel transforming growth factor-beta (TGF-β1) receptor I kinase inhibitor, LY2157299 monohydrate (LY), in patients with advanced hepatocellular carcinoma (HCC)
    Faivre, Sandrine J.
    Santoro, Armando
    Kelley, Robin Kate
    Merle, Philippe
    Gane, Ed
    Douillard, Jean-Yves
    Waldschmidt, Dirk
    Mulcahy, Mary Frances
    Costentin, Charlotte
    Minguez, Beatriz
    Papappicco, Pasqua
    Gueorguieva, Ivelina
    Cleverly, Ann
    Desaiah, Durisala
    Lahn, Michael M.
    Ameryckx, Sophie
    Benhadji, Karim A.
    Raymond, Eric
    Giannelli, Gianluigi
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [12] A phase 2 study of galunisertib, a novel transforming growth factor-beta (TGF-β) receptor I kinase inhibitor in patients with advanced hepatocellular carcinoma (HCC) and low serum alpha fetoprotein (AFP)
    Faivre, Sandrine J.
    Santoro, Armando
    Gane, Edward
    Kelley, Robin Kate
    Hourmand, I. Ivier
    Assenat, Eric
    Gueorguieva, Ivelina
    Cleverly, Ann
    Desaiah, Durisala
    Lahn, Michael M. F.
    Raymond, Eric
    Benhadji, Karim A.
    Giannelli, Gianluigi
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [13] XPO1 Inhibitor (ATG-010) Plus Chemotherapy per Investigator's Choice for Heavily Pretreated Patients with Relapsed or Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL) and Extranodal NK/T-Cell Lymphoma (ENKTL):: Preliminary Results from a Multicenter, Single-Arm, Phase Ib Study (TOUCH Trial)
    Huang, Huiqiang
    Gao, Yan
    Zhang, Huilai
    Zhou, Keshu
    Wu, Jianqiu
    Cai, Zhen
    Jing, Hongmei
    Fan, Lei
    Lou, Sai
    Fei, Yizhou
    Wang, Aihua
    Lynch, Kevin
    BLOOD, 2021, 138
  • [14] UCARTCS1A, an Allogeneic CAR T-Cell Therapy Targeting CS1 in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Translational Results from a First-in-Human Phase I Trial (MELANI-01)
    Patel, Krina
    Bharathan, Mini
    Esteva, Francisco J.
    Siegel, David
    Rossi, Adriana
    Frattini, Mark G.
    Smith, Julianne
    Brownstein, Carrie
    MOLECULAR THERAPY, 2021, 29 (04) : 59 - 60
  • [15] Intravenous and Subcutaneous Administration of RG6234, a Novel GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Biomarker Results from a Phase I Study
    Dekhtiarenko, Iryna
    Lelios, Iva
    Attig, Jan
    Sleiman, Nassim
    Lazzaro, Domenico
    Schindler, Emilie
    Eckmann, Jan
    Umana, Pablo
    Jacob, Wolfgang
    Schneider, Meike
    Carlo-Stella, Carmelo
    Mazza, Rita
    Manier, Salomon
    Facon, Thierry
    Yoon, Sung-Soo
    Koh, Youngil
    Harrison, Simon J.
    Er, Jeremy
    Pinto, Antonio
    Volzone, Francesco
    Perrone, Giulia
    Corradini, Paolo
    Cazaubiel, Titouan
    Hulin, Cyrille
    Touzeau, Cyrille
    Moreau, Philippe
    Ocio, Enrique M.
    Gaisan, Carmen Maria Montes
    Popat, Rakesh
    Leong, Sarah
    Offner, Fritz
    Otero, Paula Rodriguez
    Alfonso-Pierola, Ana
    Hutchings, Martin
    Riley, Caroline Hasselbalch
    Broske, Ann-Marie E.
    BLOOD, 2022, 140 : 10137 - 10139
  • [16] Phase Ib study evaluating safety and pharmacokinetics (PK) of the oral transforming growth factor-beta (TGF-β) receptor I kinase inhibitor LY2157299 monohydrate (LY) when combined with gemcitabine in patients with advanced cancer.
    Kozloff, Mark
    Carbonero, Rocio
    Nadal, Tamara
    Gueorguieva, Ivelina
    Cleverly, Ann
    Desaiah, Durisala
    Lahn, Michael M. F.
    Pillay, Sada
    Blunt, Al
    Tabernero, Josep
    Macarulla, Teresa
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [17] Combination of Anti-CD19 and Anti-CD20 Chimeric Antigen Receptor T Cells for Relapsed and Refractory Diffuse Larger B Cell Lymphoma: An Open-Label, Single-Arm, Phase I/II Trial
    Sang, Wei
    Shi, Ming
    Yang, Jingjing
    Cao, Jiang
    Xu, Linyan
    Yan, Dongmei
    Song, Xuguang
    Sun, Cai
    Li, Depeng
    Zhu, Feng
    Li, Zhenyu
    Zheng, Junnian
    Qiao, Jianlin
    Xu, Kailin
    BLOOD, 2019, 134
  • [18] Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon Beta, in Patients with Relapsed or Refractory Multiple Myeloma (MM), Acute Myeloid Leukemia (AML), and T-Cell Neoplasms (TCL)
    Cook, Joselle
    Peng, Kah-Whye
    Ginos, Brenda F.
    Dueck, Amylou C.
    Giers, Marissa
    Packiriswamy, Nandakumar
    Brunton, Beth
    Patnaik, Mrinal M.
    Witzig, Thomas E.
    Buadi, Francis K.
    Dispenzieri, Angela
    Gertz, Morie A.
    Go, Ronald S.
    Hayman, Suzanne R.
    Lust, John A.
    Dingli, David
    Rajkumar, S. Vincent
    Leung, Nelson
    Warsame, Rahma M.
    Gonsalves, Wilson I.
    Kourelis, Taxiarchis
    Muchtar, Eli
    Bergsagel, P. Leif
    Broski, Stephen
    Kapoor, Prashant
    Kyle, Robert A.
    Siddiqui, Mustaqeem A.
    Fonder, Amie
    Hobbs, Miriam A.
    Hwa, Yi L.
    Lin, Yi
    Kumar, Shaji K.
    Russell, Stephen J.
    Lacy, Martha Q.
    BLOOD, 2020, 136
  • [19] Anti-PD-1 Antibody (Sintilimab) Plus Histone Deacetylase Inhibitor (Chidamide) for the Treatment of Refractory or Relapsed Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (r/r-ENKTL): Preliminary Results from a Prospective, Multicenter, Single-Arm, Phase Ib/II Trial (SCENT)
    Gao, Yan
    Huang, Huiqiang
    Wang, Xiaoxiao
    Bai, Bing
    Zhang, Liling
    Xiao, Yin
    Liu, Xinxiu
    Li, Wenyu
    Xu, Wei
    Feng, Ru
    Chen, Yu
    Wu, Huijing
    Li, Jibin
    Wu, Xue
    BLOOD, 2020, 136
  • [20] Safety interim data front a three-arm phase II study evaluating safety and pharmacokinetics of the oral transforming growth factor-beta (TGF-β) receptor I kinase inhibitor LY2157299 monohydrate in patients with glioblastoma at first progression.
    Carpentier, Antoine F.
    Brandes, Alba Ariela
    Kesari, Santosh
    Sepulveda, Juan Manuel
    Wheeler, Helen
    Chinot, Oliver L.
    Cher, Lawrence
    Steinbach, Joachim Peter
    Specenier, Pol M.
    Cleverly, Ann
    Tomlin, Irene
    Desaiah, Durisala
    Lahn, Michael M. F.
    Wick, Wolfgang
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
123